GLP-1 receptor agonists have transformed weight loss treatment. The two most widely prescribed are semaglutide (the active ingredient in Wegovy and Ozempic) and tirzepatide (found in Zepbound and Mounjaro). Both are effective, but they work slightly differently.
Semaglutide mimics the GLP-1 hormone, which tells your brain you're full and slows gastric emptying. It's a single-action drug that targets one receptor. Clinical trials showed average weight loss of about 15% of body weight over 68 weeks.
Tirzepatide is a dual-action medication targeting both GLP-1 and GIP receptors. This dual mechanism may provide stronger appetite suppression and improved blood sugar control. Clinical trials showed average weight loss of about 20% of body weight — roughly a third more than semaglutide.
Both medications share similar side effects, primarily gastrointestinal: nausea, diarrhea, constipation, and stomach discomfort. These usually diminish as your body adjusts. Starting at a low dose and gradually increasing helps minimize side effects.
Brand-name versions of both medications are expensive without insurance. However, compounded versions and generic alternatives have made both more accessible. Pricing varies significantly by provider and dosage.
Both are highly effective. Tirzepatide shows slightly better weight loss results in head-to-head studies, but semaglutide has a longer track record and more long-term safety data. Your physician will recommend the best option based on your health profile, goals, and any existing conditions.
Related: Ozempic vs Wegovy · GLP-1 Weight Loss Guide · Weight Loss
Ready to take the next step?
Join the Waitlist — Get 50% Off